1. Medtech Insight
  2. >>Archive

Cutting French waste on thyroid tests:

A programme in France aimed at educating GPs about the value of thyroid tests could see a 50% reduction in the number of tests prescribed. The Ile-de-France regional union of insurance funds (Urcam) is taking action, having made a comparison between recommendations from the French national agency for healthcare accreditation and evaluation (ANAES) and its survey of actual prescribing habits in Paris and the surrounding area. It found that nearly half of all such prescriptions did not conform with the ANAES good practice recommendations and that over 40% were pointless. The Ile de France Urcam estimate that some E297,000 ($371,000) is wasted a month in prescriptions for unnecessary combined tests for thyroid stimulating hormone (TSH) and T4 tests, and a further E282,000 for unnecessary combined TSH, T3 and T4 tests. Representatives of the Urcam have now issued CD-Roms to some 13,000 healthcare professionals and are making targeted visits to high prescribers.

A programme in France aimed at educating GPs about the value of thyroid tests could see a 50% reduction in the number of tests prescribed. The Ile-de-France regional union of insurance funds (Urcam) is taking action, having made a comparison between recommendations from the French national agency for healthcare accreditation and evaluation (ANAES) and its survey of actual prescribing habits in Paris and the surrounding area. It found that nearly half of all such prescriptions did not conform with the ANAES good practice recommendations and that over 40% were pointless. The Ile de France Urcam estimate that some E297,000 ($371,000) is wasted a month in prescriptions for unnecessary combined tests for thyroid stimulating hormone (TSH) and T4 tests, and a further E282,000 for unnecessary combined TSH, T3 and T4 tests. Representatives of the Urcam have now issued CD-Roms to some 13,000 healthcare professionals and are making targeted visits to high prescribers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

EU/US Trade Deal Raises Questions For Medtech

 
• By Amanda Maxwell

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

Roche Diagnostics Growth Flattens As China Reforms Bite; Bets On US Manufacturing, CGM For Growth

 
• By Shubham Singh

Roche has taken steps to mitigate potential tariff exposure that include shifting inventories and increasing US production of medicines. The company also initiated a tech transfer for one of its most exposed products to a US manufacturing site.